DiaMedica Therapeutics
DMAC
DMAC
28 hedge funds and large institutions have $7.42M invested in DiaMedica Therapeutics in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
26% less capital invested
Capital invested by funds: $10M → $7.42M (-$2.6M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Holders
28
Holding in Top 10
–
Calls
$175K
Puts
$57K
Top Buyers
| 1 | +$30K | |
| 2 | +$28.9K | |
| 3 | +$20.8K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.36K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.12K |
Top Sellers
| 1 | -$553K | |
| 2 | -$66.6K | |
| 3 | -$53.6K | |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$52K |
| 5 |
Two Sigma Advisers
New York
|
-$45.9K |